Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9070MR)

This product GTTS-WQ9070MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9070MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14443MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ5529MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ15444MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ8706MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ2537MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ1444MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ1971MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ13000MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW